Clinical Trial Update: Indacaterol EfectIveness In COPD Patients With Tuberculosis History [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating indacaterol’s effectiveness in patients with moderate-to-severe chronic obstructive pulmonary disease who have destroyed lungs from tub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol (indacaterol)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis | Phase 3 | Status: COMPLETED | Results posted: 2015-09-18